South Korea’s Medical Tourism Surges to Record 1.17 Million Foreign Patients in 2024

South Korea’s unprecedented surge in foreign patient numbers—1.17 million in 2024 alone—represents more than just a recovery from the COVID-19 downturn. It signals the country’s arrival as a powerhouse in Asia’s high-value medical tourism sector, where advanced care, beauty innovation, and cultural soft power converge. But as the government celebrates surpassing its 2027 goals three years ahead of schedule, questions about long-term sustainability, equitable healthcare access, and regional policy priorities are coming into sharper focus.

Medical tourism is often lauded as a "high-value, low-footprint" industry. In Korea’s case, it fuses two of its strongest global exports: healthcare excellence and cultural aesthetics. Dermatology and plastic surgery—bolstered by the global appeal of K-beauty—now account for over two-thirds of foreign patient visits. Moreover, most of the demand stems from relatively affluent consumers in East Asia, especially Japan, China, and Taiwan, who are willing to pay premium prices for short, outpatient services.

The Ministry of Health and Welfare has skillfully aligned its strategy with this demand. The 2023 “Medical Korea” roadmap focused on diversifying nationalities, easing regulatory burdens, and digitizing patient services. The results speak for themselves: a 93.2% year-on-year increase and cumulative totals topping 5 million foreign patients since 2009.

Foreign Patients by Year

Top 5 Source Countries (2024)

Most Popular Medical Departments

Regional Imbalance and Systemic Risks

However, not all signs point toward unqualified success. One major concern is the growing centralization of services. Seoul accounts for over 85% of all foreign patients, while tertiary hospitals—arguably better equipped to handle complex procedures—saw a decline in use. Clinics, especially dermatology and cosmetic-focused ones, are absorbing most of the influx.

This raises equity issues in healthcare access. If resources and attention continue to flow toward profitable aesthetic procedures for foreign visitors, local patients—especially in under-served or aging regions—may face longer wait times or declining public investment. Furthermore, some critics warn of a “beauty economy bubble,” in which economic over-dependence on cosmetic medicine could leave Korea vulnerable to demand shocks or reputation risks.

Korea’s medical tourism success offers real momentum, but also demands thoughtful recalibration. Policymakers should consider expanding medical tourism infrastructure to secondary cities like Busan, Daegu, and Jeju, which already show promising growth rates. Incentivizing services beyond beauty—such as wellness, preventive care, and integrative Korean medicine—could broaden Korea’s value proposition.

Equally important is the need for robust monitoring. As foreign patient numbers climb, so too must vigilance over ethical standards, data protection, pricing transparency, and equitable care delivery for Korean citizens.

The 2024 numbers are a milestone, but they are only the beginning. South Korea has a rare opportunity to define what the next generation of global healthcare looks like—technologically sophisticated, culturally resonant, and ethically inclusive. That journey will depend not just on the number of patients served, but on how well the system serves all stakeholders, both foreign and domestic.